|Year : 2009 | Volume
| Issue : 6 | Page : 566-574
Newer trends in the management of genital herpes
Amiya Kumar Nath, Devinder Mohan Thappa
Department of Dermatology and STD, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry - 605 006, India
|Date of Web Publication||12-Nov-2009|
Devinder Mohan Thappa
Department of Dermatology and STD, JIPMER, Pondicherry - 605 006
Source of Support: None, Conflict of Interest: None
Management of genital herpes is complex. Apart from using the standard antivirals, an ideal management protocol also needs to address various aspects of the disease, including the psychological morbidity. Oral acyclovir, valacyclovir or famciclovir are recommended for routine use. Long-term suppressive therapy is effective in reducing the number of recurrences and the risk of transmission to others. Severe or disseminated disease may require intravenous therapy. Resistant cases are managed with foscarnet or cidofovir. Genital herpes in human immunodeficiency virus-infected individuals usually needs a longer duration of antiviral therapy along with continuation of highly active anti retroviral therapy (HAART). Genital herpes in late pregnancy increases the risk of neonatal herpes. Antiviral therapy and/or cesarean delivery are indicated depending on the clinical circumstance. Acyclovir appears to be safe in pregnancy. But, there is limited data regarding the use of valacyclovir and famciclovir in pregnancy. Neonatal herpes requires a higher dose of acyclovir given intravenously for a longer duration. Management of the sex partner, counseling and prevention advice are equally important in appropriate management of genital herpes. Vaccines till date have been marginally effective. Helicase-primase inhibitors, needle-free mucosal vaccine and a new microbicide product named VivaGel may become promising treatment options in the future.
Keywords: Acyclovir, Famciclovir, Genital herpes, HIV, Pregnancy, Valacyclovir
|How to cite this article:|
Nath AK, Thappa DM. Newer trends in the management of genital herpes. Indian J Dermatol Venereol Leprol 2009;75:566-74
| Introduction|| |
Genital herpes is the most common cause of ulcerative sexually transmitted infection in the world.  Appropriate management of genital herpes is complex. The most important aspect of the management revolves around the judicious use of antiviral agents.  As the results of various randomized studies come to light, treatment protocols for the management of genital herpes under different clinical circumstances undergo constant update.
Many patients with genital herpes may have atypical manifestations.  Therefore, the sensitivity and the specificity of a clinical diagnosis is unacceptably low (39% sensitivity at best with a 20% false-positive diagnosis).  It should also be borne in mind that undiagnosed cases are the most common source of new transmission.  Hence, clinical diagnosis of genital herpes should be confirmed by laboratory testing.
| Investigations|| |
Investigations should be routinely utilized to improve the diagnostic accuracy of genital herpes. They are especially useful when the manifestations of genital herpes are atypical or when met with special circumstances like neonatal herpes. ,,
Tzanck smear can be helpful in the rapid diagnosis of genital herpes lesions (by identifying multinucleate giant cells), but it is less sensitive than viral culture. Immunofluorescence staining increases the sensitivity and specificity of a Tzanck smear preparation.
Histopathology is occasionally required in chronic herpes infection in human immunodeficiency virus (HIV)-infected individuals wherein morphology and clinical course are atypical.
Viral culture is the 'gold standard' for herpes simplex virus (HSV) diagnosis. Cytopathic effects appear in 2-3 days after inoculation in human diploid fibroblast cultures or green monkey kidney cell cultures. Sensitivity of the tissue culture depends on the stage of clinical lesions - isolation is successful in about 80% of primary infections and in 25-50% of recurrent infections. Viral isolation is least successful in lesions that have begun to heal.
HSV direct detection tests include electron microscopy, HSV antigen detection (immunoperoxidase tests, immunofluorescence, enzyme immunoassay), HSV-DNA detection (DNA hybridization) and HSV-PCR.
Direct fluorescent antibody test (DFA) is used for the detection of HSV antigen in smear, tissues or culture. The sensitivity of the DFA test for the detection of HSV in genital specimens varies between 70 and 90% of culture-positive specimens.
HSV antigen is extracted from the clinical specimen with a buffered solution. The extract is added to a test device and any antigen present is immobilized on a membrane. When treated peroxidase-labeled anti-HSV monoclonal antibody with substrate is added, a colored spot is obtained on the membrane. The sensitivity of this test is slightly lower than that of enzyme-linked immunosorbent assay (ELISA).
PCR is more sensitive (four times) and faster than viral culture. Because the type of HSV infection affects prognosis and subsequent counseling, type-specific testing to distinguish HSV-1 from HSV-2 is recommended. Although PCR has been the diagnostic standard for HSV infections of the central nervous system (CNS), until now viral culture has been the test of choice for HSV genital infection. However, HSV-PCR, with its consistently and substantially higher rate of HSV detection, will likely replace viral culture as the gold standard for the diagnosis of genital herpes in people with active mucocutaneous lesions, regardless of anatomic location or viral type. 
These tests detect antibodies to HSV in blood and it includes ELISA, complement fixation test and Western blot. Accurate type-specific HSV serologic assays are based on the HSV-specific glycoprotein G2 (HSV-2) and glycoprotein G1 (HSV-1).
Serology can rule out a prior HSV infection. HSV antibodies are absent in the acute stage but gradually appear, increase over subsequent weeks and persist for life.  Seroconversion and a four-fold rise in antibody titers in acute and convalescent sera are seen after a true primary (first episode) infection.  Seroconversion in pregnancy is associated with a high risk of neonatal herpes.  Recurrent episodes are rarely associated with an increase in antibody titers. [1, Newer type-specific ELISAs can discriminate between HSV-1 and HSV-2 antibodies.  Serology is useful in recurrent lesions, atypical lesions, healing lesions, culture-negative cases, unrecognized infection and in evaluation of the sex partner.  These tests may also be used to establish whether a herpetic outbreak is due to newly acquired infection for medicolegal purpose and, in HIV-infected individuals, for deciding on suppressive therapy. , The most important application of serology is in the diagnosis of asymptomatic infections in transplant recipients and in patients receiving immunosuppressive drugs.  Disadvantages of serological tests include false-negative results (due to delayed appearance of antibody or low sensitivity), false-positive results in low-risk populations, low purity of the recombinant glycoprotein G and the potential for cross-reactivity between glycoproteins G1 and G2 in ELISA, inability to determine the route of HSV acquisition (genital or oral) and difficulty in interpretation of results in HIV and other types of immunosuppressions.  It must be remembered during interpretation of serological results that almost all HSV-2 infections are sexually acquired whereas HSV-1 antibodies indicate either an orolabial or a genital acquisition. 
| Principles of the Management of Genital Herpes|| |
The following goals are to be met during the management of patients with genital herpes:
- Inducing healing of clinical lesions
- Preventing recurrences
- Preventing transmission to others
- Sexual partner management
- Management of the psychological morbidity
- Counseling regarding the natural history of genital herpes, sexual and perinatal transmission and methods to reduce transmission
- Handling of special circumstances like herpes genitalis in HIV, pregnancy and neonatal herpes
Antiviral chemotherapy offers clinical benefits to the majority of symptomatic patients and is the mainstay of management. , Palliative measures like loose-fitting cotton underwears, cold compresses, saline bathing of the affected area, keeping the area dry and clean and topical zinc cream application should be advised.  Systemic antiviral drugs can partially control the signs and symptoms of herpes episodes when used to treat first clinical and recurrent episodes or when used as daily suppressive therapy. However, these drugs do not eradicate the latent virus. ,,
Currently, three drugs are approved for the treatment of genital herpes: acyclovir, valacyclovir and famciclovir.  Acyclovir is highly active against HSV-1 but slightly less active against HSV-2.  The antiviral activity of acyclovir is due to the intracellular conversion of acyclovir, by viral thymidine kinase, to the monophosphate, with subsequent conversion by cellular kinases to diphosphate and the active triphosphate. This active form inhibits viral DNA synthesis and replication by inhibiting the herpes virus DNA polymerase enzyme as well as by being incorporated into the viral DNA causing premature DNA chain termination. The whole process is highly selective for infected cells because the initial activation needs viral thymidine kinase and, for the same reason, acyclovir has no activity against latent virus. Compared with acyclovir, penciclovir is 100-160 times less potent in inhibiting viral DNA polymerase but compensates for that by a longer half-life and higher intracellular concentration. Penciclovir inhibits viral DNA synthesis through irreversible and competitive inhibition of DNA polymerase rather than DNA chain termination.  Penciclovir is not indicated for HSV-2 infections. 
Valacyclovir and famciclovir are prodrugs of acyclovir and penciclovir, respectively. They have enhanced absorption after oral administration and higher oral bioavailability, thereby allowing for lower dosage and lesser frequency of administration (oral bioavailability of acyclovir is 10-20% and that for valacyclovir is five times higher  ). Topical acyclovir preparations are less useful and are not recommended.  Acyclovir resistance is most commonly due to mutation in the viral thymidine kinase and rarely due to mutation in viral DNA polymerase. In acyclovir resistance, valacyclovir and famciclovir are also ineffective. In spite of reports of treatment failure, resistance has never been a major problem in genital herpes. 
Forcarnet inhibits viral DNA polymerase directly without requiring activation by viral thymidine kinase.  Therefore, it is effective in acyclovir-resistant HSV infections. Foscarnet resistance is rare. Cidofovir, after activation by cellular kinases, inhibits viral DNA polymerase and is useful in acyclovir- and foscarnet-resistant cases. It is given intravenously (IV) once a week. Topical cidofovir 1% gel is also effective in acyclovir-resistant HSV infections [Figure 1]. 
Antivirals may be used in the following ways [Table 1]:
- Symptomatic management to reduce symptoms and improve healing
- Episodic (intermittent therapy) to abort or reduce the duration of episodes
- Continuous suppressive therapy to prevent recurrences
| First Clinical Episode of Genital Herpes|| |
Many persons with first-episode herpes have severe or prolonged symptoms. Therefore, patients with initial genital herpes should receive antiviral therapy. 
| Established HSV-2 Infection|| |
Antiviral therapy for recurrent genital herpes can be administered either episodically to ameliorate or shorten the duration of lesions or continuously as suppressive therapy to reduce the frequency of recurrences.  The patient should also be counseled regarding the triggering factors and measures to avoid them. 
| Episodic Therapy for Recurrent Genital Herpes|| |
Effective episodic treatment of recurrent herpes requires initiation of therapy within 1 day of lesion onset or during the prodrome that precedes some outbreaks. The maximal viral replication occurs within 24 h of the first prodromal symptom.  Patient-initiated episodic therapy started during the onset of prodromal symptoms, which most patients can be easily taught to identify, is preferred by many clinicians because it takes advantage of the window period between onset of prodromal symptoms and clinically visible lesions of herpes (which is usually 12-24 h).  Episodic treatment with nucleoside analogs is usually given for 3-5 days. However, single-day patient-initiated episodic treatment (e.g., with famciclovir 1000 mg twice daily  or valacyclovir 2000 mg twice daily  ) has been found to be a better option, with better compliance and outcomes. ,
| Suppressive Therapy for Recurrent Genital Herpes|| |
Suppressive therapy is indicated when recurrent genital herpes is frequent (≥ 6 recurrences in 1 year), severe, distressing or associated with distressing prodromes. Other indications are herpetic lesions in the last trimester, patients with psychological and psychosexual problems due to the infection and immunocompromised patients. The risk of transmission of the virus to the sex partner is reduced as suppressive therapy reduces asymptomatic viral shedding.
Long-term antiviral prophylaxis may be started any time and continued for an unspecified duration.  Safety and efficacy have been documented among patients receiving daily therapy with acyclovir for as long as 6 years and with valacyclovir or famciclovir for 1 year. Quality of life of patients with frequent recurrences is better in those who receive suppressive therapy than in those who receive episodic treatment. In a study, 72% of the patients preferred to take suppressive therapy over episodic therapy.  Long-term suppression is reported to reduce clinical outbreaks of genital herpes and subclinical shedding by 80 and 95%, respectively.  The frequency of recurrent genital herpes outbreaks diminishes over time in many patients. 
Breakthrough episodes during therapy should prompt one to look for poor compliance, need to adjust therapy, resistance or a mistaken diagnosis. A minimum of 3 months to 1 year of daily therapy is warranted for any efficacy.  Some patients desire short-term suppression for a duration of 1 month. Annual evaluation is required and cessation of therapy (or drug holiday) should be discussed with patients who are well controlled for a long time.  Some authors recommend that suppressive therapy should be discontinued after 12-24 months in order to assess the ongoing frequency of recurrences. 
Valacyclovir appears to be somewhat better than famciclovir for the suppression of genital herpes and associated shedding.  However, valacyclovir 500 mg once a day may be less effective than other acyclovir or valacyclovir regimens in patients with very frequent (> 10 in a year) recurrences. 
| Severe Disease|| |
IV acyclovir therapy is recommended in patients who have severe HSV disease or complications that necessitate hospitalization (e.g., disseminated infection, pneumonitis or hepatitis) or CNS complications (e.g., meningitis or encephalitis). The recommended regimen is acyclovir 5-10 mg/kg body weight IV every 8 h for 2-7 days or until clinical improvement is observed, followed by oral antiviral therapy to complete at least 10 days of total therapy. 
| HIV Infection|| |
Antiretroviral therapy reduces the severity and frequency of symptomatic genital herpes, but frequent subclinical shedding still occurs. Suppressive or episodic therapy with oral antiviral agents is effective is reducing HSV shedding, is safe and well tolerated and may provide additional benefit by decreasing HIV-1 levels in the blood and genital tract. Treatment should be continued till all the lesions heal, which may take a significantly longer duration compared with genital herpes in the immunocompetent individuals. Some specialists suggest that HSV type-specific serology should be offered to HIV-positive persons during their initial evaluation and suppressive antiviral therapy should be considered in those who have HSV-2 infection. ,
Acyclovir resistance is much higher (3.6-10.9%) in patients with HIV compared with immunocompetent hosts (< 1%). The scenario did not change even after the introduction of HAART.  Cases of thrombotic microangiopathy reported earlier in the literature occurring following valacyclovir therapy in the immunocompromised individuals were related to a high dose of valacyclovir given for a prolonged duration. With the currently recommended dosage, such adverse effects are unlikely (patient on high-dose valacyclovir should, however, be monitored for such adverse effects). Valacyclovir has been FDA approved for use in HSV infections in HIV. 
| Genital Herpes in Pregnancy|| |
The risk of neonatal transmission is low if genital herpes occurs in the first and second trimester.  However, patients with genital herpes after 34 weeks of gestation and those who have not completed at least 4 weeks of acyclovir therapy before delivery are at a high risk of transmitting the infection to the neonates.  Cesarean delivery is indicated for such cases, but it does not completely eliminate the risk. The best policy would be to continue acyclovir till delivery and perform cesarean section at full term.  Elective cesarean delivery is especially indicated if active HSV lesions are present during or within 2 weeks of labour. 
Acyclovir, valacyclovir and famciclovir are Pregnancy Category B drugs.  Safety of these drugs in pregnancy has not been definitively established but available data do not suggest major birth defects due to acyclovir.  The benefits much outweigh the risk.  Acylcovir attains good concentration in the fetus.  Data regarding valacyclovir and famciclovir are limited. However, safety of acyclovir may be extended to valacylcovir as it is a prodrug of acyclovir. 
Antiviral (acyclovir 400 mg tid for 7-14 days or valacyclovir 1 g bid for 7-14 days) therapy is recommended for women with symptomatic primary or first-episode HSV infection during pregnancy.  Symptomatic recurrent HSV should be treated with acyclovir 400 mg tid for 5 days or valacyclovir 500 mg bid for 5 days.  For women with frequent or severe recurrences, especially after the first trimester, daily suppressive therapy (acyclovir 400 mg tid or valacyclovir 500 mg bid) from 36 weeks of gestation till delivery may be indicated.  Andrews et al. reported that administration of valacyclovir (500 mg bd) beginning at 36 weeks gestation till delivery in women with a history of recurrent genital HSV reduced the number of subsequent clinical HSV recurrences. 
Prevention of neonatal herpes involves one or more of the following measures: serology for identifying those women at risk of acquiring new infection, recommendation of abstinence or protective condoms or antiviral prophylaxis in the context of a HSV-2-seropositive man and HSV-2-seronegative woman (seroincompatible), prophylactic antivirals from the 36 th week of gestation in pregnant females at a high risk of HSV outbreaks during labour, antiviral treatment of HSV infections during late pregnancy, abstinence from oral sex in HSV-1-seroincompatible couples, thorough evaluation (including speculoscopy) for herpetic lesions during labour, avoiding exposure of the infant to herpetic lesions during delivery by performing cesarean section, providing occlusive dressing for nongenital lesions during labour, avoidance of iatrogenic trauma to the fetus and refraining health care workers with visible herpetic lesions from providing postnatal care. ,
| Neonatal Herpes|| |
Infants suspected to have been exposed to HSV during birth should be followed carefully in consultation with a specialist and cultures of mucosal surfaces would be desirable. Some specialists recommend the use of acyclovir for infants born to women who acquired HSV near term. 
Neonates delivered through an infected birth canal should be screened between 24 and 48 h of age with viral cultures of the eyes, nasopharynx, mouth and rectum. ,,, Treatment with systemic acyclovir should be started promptly. The recommended regimen for infants treated for known or suspected neonatal herpes is acyclovir 20 mg/kg body weight IV every 8 h for 21 days for disseminated and CNS disease or for 14 days for disease limited to the skin and mucous membranes. 
| Drug Resistance|| |
If lesions persist or recur in a patient receiving antiviral treatment, HSV resistance should be suspected and a viral isolate should be obtained for sensitivity testing.  All acyclovir-resistant strains are resistant to valacyclovir and the majority are resistant to famciclovir. In the case of clinical resistance, virological studies with resistance testing should be carried out. This will help a clinician decide whether to give a high dose oral or intravenous acyclovir, if the strain shows complete or intermediate sensitivity, or to switch to an alternative agent like foscarnet.  Foscarnet, 40 mg/kg body weight IV every 8 h until clinical resolution is attained is frequently effective for the treatment of acyclovir-resistant genital herpes. Topical cidofovir gel 1% applied to the lesions once daily for five consecutive days might also be effective.  A combination of multidrug therapy has also been tried in resistant HSV disease. 
| Management of Sex Partners|| |
The sex partners of patients who have genital herpes can benefit from evaluation and counseling. Symptomatic sex partners should be evaluated and treated in the same manner as patients who have genital lesions. Asymptomatic sex partners of patients who have genital herpes should be questioned concerning histories of genital lesions and offered type-specific serologic testing for HSV infection. 
| Counseling|| |
Counseling of infected persons and their sex partners is critical to the management of genital herpes.  The goal of counseling is to help patients cope with the infection and prevent sexual and perinatal transmission. 
The following recommendations apply to counseling of persons with HSV infection:
- Explain and educate about the nature of genital herpes, the potential for recurrent episodes, asymptomatic viral shedding and the risks of sexual transmission.
- Explain the role of suppressive or episodic therapy in persons experiencing a first episode of genital herpes.
- Encourage to inform the sex partners.
- Explain the need to abstain from sexual activity with uninfected partners when lesions or prodromal symptoms are present.
- Explain that latex condoms reduce the risk for genital herpes transmission.
- Evaluate the sex partners, even in the absence of symptoms, by serology to identify serocompatibility.
- Educate regarding neonatal herpes.
- Seropositive but clinically asymptomatic patients should receive the same counseling message.
In addition, patients should be taught about the clinical manifestations and prodromal symptoms of genital herpes. 
| Prevention|| |
- Sexual abstinence is the only method for absolute prevention of genital herpes.
- Contact should be avoided when active lesions are present. Avoid contact until re-epithelialization has occurred.
- Use of condoms and spermicidal foams is recommended in patients who have a history of recurrent herpes genitalis.
- Condoms are effective only if they cover all the lesions and are more effective at protecting susceptible females from HSV transmission than susceptible males.
- If both partners had genital herpes, protective measures are not necessary if both carry the same virus type and active lesions are not present.
- Having herpes in one area is not protective against acquiring the infection in another location.
| New Advances|| |
Vaccination, at least in theory, is the best method for preventing virus spread, but this strategy has been only marginally successful in genital herpes.  The HSV candidate vaccines tested till now were mostly purified subunit vaccines and/or recombinant envelope glycoproteins (such as gB and gD). In many experiments performed in mice, guinea pigs and rabbits, clear-cut protection against acute virus challenge was demonstrated along with the reduction of the extent of latency. The immunotherapeutic effect of herpes vaccines seems less convincing. However, the introduction of new adjuvants, which shift the cytokine production of helper T-cells toward the stimulation of cytotoxic T-cells, reveals a promising development. 
Recently, the results of two controlled trials of an HSV type 2 (HSV-2) glycoprotein D (gD) vaccine revealed that vaccination reduced the rate of acquisition of genital herpes disease, but it did so only among HSV-seronegative women.  The vaccine did not reduce the risk of disease among men and did not add to the protection provided by a previous HSV-1 infection in women.
Resiquimod and imiquimod have been tried topically and have been found to decrease the median lesions and the shedding rate without any influence on the recurrence duration. 
| Future Trends|| |
Helicase-primase inhibitors are new nonnucleoside antivirals that target the helicase-primase complex critically involved in HSV DNA replication. Results from animal studies are encouraging.  They may prove to be the new generation of anti-HSV drugs with improved efficacy, less toxicity, better cost-effectiveness and more convenient administration.  A study using BAY 57-1293, a helicase-primase inhibitor, in animal models of ocular HSV-1 infection showed that it is more effective than valacyclovir with a good safety profile. 
Zhang et al. tested a novel needle-free mucosal vaccine containing synthetic peptide epitopes of HSV-2 extended with an agonist of Toll-like receptor 2 (TLR-2) that are abundantly expressed by dendritic and epithelial cells of the vaginal mucosa. After intravaginal inoculation, there was the development of protective immunity (local and systemic CD8+ T cells response) against HSV-2. 
A new microbicide product named VivaGel (containing SPL7013 as the active ingredient) has been showing promising efficacy and safety in initial animal and human studies. 
| Conclusion|| |
Genital herpes infection is treatable, but not curable. Prolonged suppressive therapy prevents recurrences and reduces asymptomatic viral shedding. Genital herpes in pregnancy, HIV and neonatal herpes pose special problems; however, treatment with standard antiviral drugs appears to be safe and effective in such circumstances. The psychological aspect of genital herpes infection should be addressed and professional help may be sought if required. Partner management is important. Newer therapeutic options appear to be interesting development but what remains challenging is to achieve cure.
| References|| |
|1.||Fatahzadeh M, Schwartz RA. Human herpes simplex virus infections: Epidemiology, pathogenesis, symptomatology, diagnosis, and management. J Am Acad Dermatol 2007;57:737-63; quiz 764-6. |
|2.||Kaliaperumal K. Recent advances in management of genital ulcer disease and anogenital warts. Dermatol Ther 2008;21:196-204. |
|3.||Gupta R, Warren T, Wald A. Genital herpes. Lancet 2007;370:2127-37. |
|4.||Gupta S, Kumar B. Genital herpes simplex infections. In: Kumar B, Gupta S, editors. Sexually transmitted infections. New Delhi: Elsevier; First edition. 2005. p. 191-214. |
|5.||Sundharam JA. Herpes Genitalis. In: Sharma VK, editor. Sexually Transmitted Diseases and AIDS. First edition. New Delhi: Viva books Pvt Ltd; 2003. p. 259-72. |
|6.||Strick LB, Wald A. Diagnostics for herpes simplex virus: is PCR the new gold standard. Mol Diagn Ther 2006;10:17-28. |
|7.||Brown ZA, Gardella C, Wald A, Morrow RA, Corey L. Genital herpes complicating pregnancy. Obstet Gynecol 2005;106:845-56. |
|8.||CDC. Sexually transmitted diseases treatment guidelines, MMWR 2006: 55: No. RR-11. |
|9.||Gupta R, Wald A. Genital herpes: antiviral therapy for symptom relief and prevention of transmission. Expert Opin Pharmacother 2006;7:665-75. |
|10.||Martinez V, Caumes E, Chosidow O. Treatment to prevent recurrent genital herpes. Curr Opin Infect Dis 2008;21:42-8. |
|11.||Tyring S, Berger T, Yen-Moore A, Tharp M, Hamed K. Single-day therapy for recurrent genital herpes. Am J Clin Dermatol 2006;7:209-11. |
|12.||Romanowski B, Marina RB, Roberts JN; Valtrex HS230017 Study Group. Patients' preference of valacyclovir once-daily suppressive therapy versus twice daily episodic therapy for recurrent genital herpes. Sex Transm Dis 2003;30:226-31. |
|13.||Strick LB, Wald A, Celum C. Management of herpes simplex virus type 2 infection in HIV type 1-infected persons. Clin Infect Dis 2006;43:347-56. |
|14.||Stone KM, Reiff-Eldridge R, White AD, Cordero JF, Brown Z, Alexander ER, et al. Pregnancy outcomes following systemic prenatal acyclovir exposure: Conclusions from the international acyclovir pregnancy registry, 1984-1999. Birth Defects Res A Clin Mol Teratol 2004;70:201-7. |
|15.||Andrews WW, Kimberlin DF, Whitley R, Cliver S, Ramsey PS, Deeter R. Valacyclovir therapy to reduce recurrent genital herpes in pregnant women. Am J Obstet Gynecol 2006;194:774-81. |
|16.||Freij BJ. Management of neonatal herpes simplex virus infections. Indian J Pediatr 2004;71:921-6. |
|17.||Sheffield JS, Hill JB, Hollier LM, Laibl VR, Roberts SW, Sanchez PJ, et al. Valacyclovir prophylaxis to prevent recurrent herpes at delivery: A randomized clinical trial. Obstet Gynecol 2006;108:141-7. |
|18.||Little SE, Caughey AB. Acyclovir prophylaxis for pregnant women with a known history of herpes simplex virus: A cost-effectiveness analysis. Am J Obstet Gynecol 2005;193:1274-9. |
|19.||Reyes M, Shaik NS, Graber JM, Nisenbaum R, Wetherall NT, Fukuda K, et al. Task Force on Herpes Simplex Virus Resistance. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med 2003;163:76-80. |
|20.||Gottlieb SL, Douglas JM Jr, Foster M, Schmid DS, Newman DR, Baron AE, et al. Project RESPECT Study Group. Incidence of herpes simplex virus type 2 infection in sexually transmitted disease (STD) clinics and the effect of HIV/STD risk-reduction counseling. J Infect Dis 2004;190:1059-67. |
|21.||Rajcáni J, Durmanová V. Developments in herpes simplex virus vaccines: old problems and new challenges. Folia Microbiol (Praha) 2006;51:67-85. |
|22.||Bernstein DI, Aoki FY, Tyring SK, Stanberry LR, St-Pierre C, Shafran SD, et al. Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clin Infect Dis 2005;40:1271-81. |
|23.||Chakrabarty A, Pang KR, Wu JJ, Narvaez J, Rauser M, Huang DB, et al. Emerging therapies for herpes viral infections (types 1-8). Expert Opin Emerg Drugs 2004;9:237-56. |
|24.||Kaufman HE, Varnell ED, Gebhardt BM, Thompson HW, Atwal E, Rübsamen-Waigmann H, et al. Efficacy of a helicase-primase inhibitor in animal models of ocular herpes simplex virus type 1 infection. J Ocul Pharmacol Ther 2008;24:34-42. |
|25.||Zhang X, Chentoufi AA, Dasgupta G, Nesburn AB, Wu M, Zhu X, et al. A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8(+) T cells and protects against herpes simplex virus type 2 challenge. Mucosal Immunol 2009;2:129-43. |
|This article has been cited by|
||Approach to the diagnosis and treatment of vulvar pain
| ||Claire S. Danby,Lynette J. Margesson |
| ||Dermatologic Therapy. 2010; 23(5): 485 |
|[Pubmed] | [DOI]|
|| Approach to the diagnosis and treatment of vulvar pain
| ||Danby, C.S., Margesson, L.J. |
| ||Dermatologic Therapy. 2010; 23(5): 485-504 |